SYNTHESIS AND DISTRIBUTION OF DRUGS OF ABUSE AND RELATED COMPOUNDS RELEASE DATE: November 14, 2002 NOTICE: NOT-DA-03-023 National Institute on Drug Abuse (NIDA) (http://www.nida.nih.gov) The National Institute on Drug Abuse (NIDA) is soliciting proposals from qualified organizations having the capability to acquire and synthesize labeled and unlabeled drugs of abuse and other chemical compounds including opioid and related neuropeptides. Qualified organizations must also be able to check the stability and purity of the compounds, maintain and store the compound inventory under secure conditions, and distribute the compounds to research investigators as directed by the NIDA Project Officer. Qualified organizations must have the proper facilities, equipment and experience to complete the above-described tasks. As some of the compounds may be scheduled under the Controlled Substances Act, demonstration of proper DEA registration and adequate security is mandatory. In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. It is anticipated that one cost reimbursement, completion type contract will be awarded for a period of five years with options for additional quantities of work each year. RFP No. N01DA-3-7736 will be available electronically on or about December 11, 2002, and may be accessed through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the NIDA website at the following address: (URL: http://www.nida.nih.gov/RFP/RFPList.html). Please note that the RFP for this acquisition will be streamlined to include only the Work Statement, Deliverables, Reporting Requirements, Special Requirements, Mandatory Qualifications, Technical Evaluation Criteria, and other necessary Proposal Preparation Instructions. However, all information required for the submission of an offer will be contained in or accessible through the electronic RFP package. Response to the RFP will be due on or about January 24, 2003. This advertisement does not commit the Government to award a contract. See note No. 26. Point of Contact: David T. Lisle, Contract Specialist Contracts Management Branch, OPRM National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 3105, MSC 9543 Bethesda, MD 20892-9543 E-mail address: DL115Q@nih.gov Phone: (301) 443-6677 Fax: (301) 443-7595
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |